Radioactive drug for advanced neuroendocrine and other cancers
Treatments studied
Part of Brain & nervous system, Cancer, Ear, nose & throat, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer that has spread or cannot be removed by surgery (including certain GI neuroendocrine tumors, pheochromocytoma/paraganglioma, small cell lung cancer, kidney cancer, or specific head and neck cancers).
- For small cell lung cancer or most kidney cancers, you must have already tried at least one standard treatment (like chemo, immunotherapy, or targeted therapy).
- Your cancer must have shown growth or worsening symptoms in the last 3 years.
- You need to have a special PET scan showing that at least half of your visible tumors have a specific marker (somatostatin receptor).
- You are 18 or older, able to do daily activities (ECOG 0-1), and have adequate organ function (like blood counts, liver, and kidney).
- If you have HIV, hepatitis B, or hepatitis C, it must be controlled or treated. You also need to agree to use contraception if you can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
This trial tests a new type of radiation therapy for advanced neuroendocrine cancers that have not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a radioactive treatment (Lutathera) for people with certain neuroendocrine tumors (NETs) that are not in the stomach or intestines)Skip to content
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.